InsiderTrades.com logo
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
Rainer M. Erdtmann net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Rainer Erdtmann Biography and Net Worth

COO of Biomea Fusion
Prior to founding Biomea Fusion in 2017, Ramses and Tom built-up Point Sur Investors, a long-only biotech investment fund focused solely on innovative therapies. Ramses also worked together with Tom at Pharmacyclics, where he most recently served as the Executive Vice President of Corporate Affairs. Ramses helped grow the company from approximately 40 employees with a market cap of $40M in 2009 to 650 employees and a market cap of $21B in 2015, when the company merged with AbbVie, Inc. He was involved in the operational expansion of the company and oversaw various departments during the growth phase including Finance, HR, Legal, Communications, IR, Facilities, Events, and IT. Prior to joining Pharmacyclics, Inc., Ramses managed assets for US high net-worth equity investors and large European closed-end funds. Ramses began his career at Commerzbank AG in Germany, where he was an investment banker and portfolio manager for international clients. He earned the Diplom Kaufmann degree with distinction in Finance and Banking from the Westfaelische Wilhelms Universität of Muenster, Germany.

What is Rainer M. Erdtmann's net worth?

The estimated net worth of Rainer M. Erdtmann is at least $819,916.02 as of August 23rd, 2021. Mr. Erdtmann owns 76,059 shares of Biomea Fusion stock worth more than $819,916 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Erdtmann may own. Learn More about Rainer M. Erdtmann's net worth.

How do I contact Rainer M. Erdtmann?

The corporate mailing address for Mr. Erdtmann and other Biomea Fusion executives is , , . Biomea Fusion can also be reached via phone at 650-980-9099 and via email at [email protected]. Learn More on Rainer M. Erdtmann's contact information.

Has Rainer M. Erdtmann been buying or selling shares of Biomea Fusion?

Rainer M. Erdtmann has not been actively trading shares of Biomea Fusion during the past quarter. Most recently, on Monday, August 23rd, Rainer M. Erdtmann bought 24,000 shares of Biomea Fusion stock. The stock was acquired at an average cost of $13.20 per share, with a total value of $316,800.00. Following the completion of the transaction, the chief operating officer now directly owns 76,059 shares of the company's stock, valued at $1,003,978.80. Learn More on Rainer M. Erdtmann's trading history.

Who are Biomea Fusion's active insiders?

Biomea Fusion's insider roster includes Rainer Erdtmann (COO), and Franco Valle (CFO). Learn More on Biomea Fusion's active insiders.

Are insiders buying or selling shares of Biomea Fusion?

In the last twelve months, insiders at the sold shares 3 times. They sold a total of 200,000 shares worth more than $6,780,750.00. The most recent insider tranaction occured on May, 31st when Major Shareholder A2a Pharmaceuticals, Inc. sold 75,000 shares worth more than $2,535,750.00. Insiders at Biomea Fusion own 26.3% of the company. Learn More about insider trades at Biomea Fusion.

Information on this page was last updated on 5/31/2023.

Rainer M. Erdtmann Insider Trading History at Biomea Fusion

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2021Buy24,000$13.20$316,800.0076,059View SEC Filing Icon  
8/17/2021Buy14,000$10.79$151,060.00310,736View SEC Filing Icon  
4/15/2021Buy176,470$17.00$2,999,990.00View SEC Filing Icon  
See Full Table

Rainer M. Erdtmann Buying and Selling Activity at Biomea Fusion

This chart shows Rainer M Erdtmann's buying and selling at Biomea Fusion by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biomea Fusion Company Overview

Biomea Fusion logo
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $10.78
Low: $10.39
High: $10.90

50 Day Range

MA: $14.72
Low: $10.47
High: $18.85

2 Week Range

Now: $10.78
Low: $8.13
High: $43.69

Volume

583,151 shs

Average Volume

981,455 shs

Market Capitalization

$386.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.